What is the optimal management for a chronic kidney disease patient with concentric left ventricular hypertrophy, normal systolic function (ejection fraction 63%), grade I diastolic dysfunction, mildly reduced right ventricular systolic function, normal pulmonary artery pressure, and normal IVC compressibility?

Optimal Management of CKD with Concentric LVH and Preserved Ejection Fraction

Start an SGLT2 inhibitor immediately if eGFR ≥20 mL/min/1.73m² and add a RAS inhibitor (ACEi or ARB) if albuminuria is present, while aggressively controlling blood pressure to target <130/80 mmHg. 1

Primary Therapeutic Interventions

SGLT2 Inhibitors: First-Line Therapy

• Initiate an SGLT2 inhibitor regardless of diabetes status if eGFR ≥20 mL/min/1.73m², as this represents the strongest evidence-based intervention for CKD-associated cardiomyopathy with proven cardiovascular and renal benefits. 1

• SGLT2 inhibitors reduce left ventricular hypertrophy and improve ejection fraction in patients with diabetes and mild CKD, with ongoing investigation in advanced CKD stages. 2

• Continue SGLT2i even if eGFR falls below 20 mL/min/1.73m² once initiated, unless intolerance or kidney replacement therapy begins. 1

• Withhold temporarily during prolonged fasting, surgery, or critical illness due to ketosis risk. 1

RAS Inhibition Strategy

• Add ACEi or ARB at maximum tolerated dose if albuminuria ≥30 mg/g (A2-A3) to address the underlying CKD and reduce cardiovascular risk. 1

• Use the highest approved dose that is tolerated, as proven benefits were achieved at these doses in clinical trials. 1

• Monitor serum creatinine, potassium, and blood pressure within 2-4 weeks of initiation or dose increase. 1

• Continue therapy unless creatinine rises >30% within 4 weeks, symptomatic hypotension occurs, or uncontrolled hyperkalemia (>6.0 mmol/L) develops despite medical management. 1

• Continue ACEi/ARB even when eGFR falls below 30 mL/min/1.73m² unless specific contraindications arise. 1

Mineralocorticoid Receptor Antagonist Consideration

• Add a nonsteroidal MRA (finerenone) if albuminuria persists >30 mg/g despite maximum tolerated RASi, provided eGFR >25 mL/min/1.73m² and serum potassium is normal. 1

• This applies particularly if the patient has type 2 diabetes, though emerging evidence supports use in non-diabetic CKD with persistent albuminuria. 1

Blood Pressure Management

Target and Monitoring

• Achieve blood pressure <130/80 mmHg using the above agents as first-line therapy, as hypertension is the primary driver of pressure overload causing concentric LVH in CKD. 3, 4

• Pressure overload results from preexisting hypertension, loss of vascular elasticity, and vascular calcifications leading to increased pulse pressure. 3

• The concentric LVH pattern with preserved EF (63%) indicates predominantly pressure overload rather than volume overload, making BP control paramount. 5, 4

Addressing Volume Status and Anemia

Volume Assessment

• Normal IVC compressibility indicates euvolemia, so aggressive diuresis is not indicated unless clinical signs of congestion develop. 6

• Monitor for fluid retention as CKD progresses, as volume overload contributes to hyperdynamic state and LVH progression. 3

Anemia Correction

• Evaluate and correct anemia if present, as anemia correction with erythropoietin determines LVH reduction in CKD patients. 3

• Anemia contributes to volume overload and hyperdynamic circulation, exacerbating LVH. 3

Management of Mineral Metabolism

• Screen and treat mineral metabolism disorders including hypocalcemia, hyperphosphatemia, low vitamin D, and secondary hyperparathyroidism, as these are specific CKD-related risk factors for LVH. 3

• In hemodialysis patients, calcimimetic etelcalcetide resulted in significant reduction in left ventricular mass. 2

Diastolic Dysfunction Management

• Grade I diastolic dysfunction with preserved EF represents early HFpEF, which is the most common left ventricular disorder in CKD patients. 5

• The bidirectional relationship between CKD and HFpEF means CKD is a risk factor for HFpEF and impacts outcomes. 5, 7

• SGLT2 inhibitors offer cardiovascular and renal benefits specifically for the HFpEF-CKD phenotype. 5, 7

Right Ventricular Dysfunction Consideration

• Mildly reduced RV systolic function with normal PA pressure suggests intrinsic RV involvement rather than pulmonary hypertension-related dysfunction. 1

• Monitor for progression, as RV dysfunction in CKD can result from systemic inflammation, neurohormonal activation, and hemodynamic changes. 7

• Optimize left-sided filling pressures and volume status to prevent secondary RV dysfunction. 1

Critical Monitoring Parameters

• Check eGFR, serum creatinine, potassium, and sodium every 2-4 weeks when initiating or titrating RASi or MRA. 1

• Hyperkalemia associated with RASi can often be managed with potassium-lowering measures rather than discontinuing therapy. 1

• The reversible decrease in eGFR on SGLT2i initiation is generally not an indication to discontinue therapy. 1

Agents to Avoid

• Never use NSAIDs in this population, as they precipitate acute kidney injury and accelerate CKD progression. 6

• Avoid nephrotoxic agents and contrast exposure when possible. 8

Long-Term Strategy

• β-blockers improve outcomes in HFrEF across all CKD stages, but their role in preserved EF with only mild RV dysfunction is less clear; consider if heart rate is elevated or if progression to reduced EF occurs. 8

• Cardiovascular involvement is present in about 80% of prevalent hemodialysis patients and is evident since CKD stage IIIb-IV. 9

• Combined cardiology-nephrology care improves management of patients with cardiac dysfunction and CKD. 8

• LVH in CKD represents an independent risk factor for arrhythmias, sudden death, heart failure, and ischemic heart disease, making aggressive management essential. 3, 4